BBIO•benzinga•
BridgeBio Pharma Has Dosed The First Asymptomatic Participant With A Known Pathogenic Transthyretin Variant, Which May Lead To Transthyretin Amyloid Disease In ACT-EARLY Study With Acoramidis
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 13, 2025 by benzinga